Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Department of Anesthesiology, Amsterdam University Medical Center (AUMC), Location AMC, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands.
Int J Mol Sci. 2021 Mar 3;22(5):2519. doi: 10.3390/ijms22052519.
The aim of pharmacological conditioning is to protect the heart against myocardial ischemia-reperfusion (I/R) injury and its consequences. There is extensive literature that reports a multitude of different cardioprotective signaling molecules and mechanisms in diverse experimental protocols. Several pharmacological agents have been evaluated in terms of myocardial I/R injury. While results from experimental studies are immensely encouraging, translation into the clinical setting remains unsatisfactory. This narrative review wants to focus on two aspects: (1) give a comprehensive update on new developments of pharmacological conditioning in the experimental setting concentrating on recent literature of the last two years and (2) briefly summarize clinical evidence of these cardioprotective substances in the perioperative setting highlighting their clinical implications. By directly opposing each pharmacological agent regarding its recent experimental knowledge and most important available clinical data, a clear overview is given demonstrating the remaining gap between basic research and clinical practice. Finally, future perspectives are given on how we might overcome the limited translatability in the field of pharmacological conditioning.
药理学预处理的目的是保护心脏免受心肌缺血再灌注(I/R)损伤及其后果的影响。有大量文献报道了在不同的实验方案中存在多种不同的心脏保护信号分子和机制。已经有几种药理学药物在心肌 I/R 损伤方面进行了评估。尽管实验研究的结果令人非常鼓舞,但转化为临床环境仍然不尽如人意。本综述重点关注两个方面:(1)在实验环境中全面更新药理学预处理的新进展,重点关注过去两年的最新文献;(2)简要总结这些心脏保护物质在围手术期的临床证据,突出其临床意义。通过直接对比每种药理学药物的最新实验知识和最重要的现有临床数据,清晰地展示了基础研究与临床实践之间仍然存在的差距。最后,对如何克服药理学预处理领域中有限的可转化性提出了未来展望。